Myth: All Stem Cell Clinics Are the Same

What This Article Covers

"Stem cell clinic" is used as if it describes one kind of place, but it covers an enormous range: hospital-based cell therapy programs running FDA-approved products, academic centers conducting IRB-approved clinical trials, and storefront clinics selling unapproved "stem cell" injections directly to consumers with no independent oversight at all. These operate under different rules, different evidence standards, and — as documented in peer-reviewed case reports and regulatory enforcement actions — different safety records. Treating them as interchangeable is the myth; understanding what actually separates them is how a patient protects themselves.

The Myth

The claim goes something like this: stem cells are stem cells, so any clinic offering them is offering roughly the same thing, just maybe at a different price. Under this view, a clinic's marketing claims, location, or client reviews are the main things worth comparing. This framing treats regulatory status, cell processing, and clinical evidence as irrelevant details rather than as the core differences they actually are.

The Reality

In practice, clinics offering "stem cell" procedures fall into very different regulatory and evidentiary categories:

• FDA-approved/licensed cellular therapies. A limited number of cell and gene therapy products have gone through the FDA's full biologics licensing pathway — meaning manufacturers submitted clinical trial data on safety and effectiveness before marketing. The FDA maintains a public list of these approved products, mostly for blood cancers and a handful of other specific, well-defined conditions.
• Legitimate clinical trials. Other reputable centers offer investigational cell therapies only within clinical trials that have Institutional Review Board (IRB) oversight, informed consent processes, and FDA-cleared Investigational New Drug (IND) status. These trials are testing therapies that are not yet approved, but they come with safety monitoring, data reporting, and ethical review built in.
• Unapproved, direct-to-consumer clinics. A large and well-documented segment of the market sells "stem cell" procedures — frequently derived from a patient's own fat or bone marrow — directly to consumers, often claiming exemption from FDA premarket review on the theory that the cells are only "minimally manipulated" and used for a "homologous" purpose. The FDA has repeatedly stated that many such products do not qualify for that exemption, and it has issued public safety communications and warning letters to clinics marketing unapproved regenerative medicine products with unsubstantiated claims.

A widely cited 2016 study published in Cell Stem Cell identified hundreds of U.S. businesses marketing stem cell interventions directly to consumers, most without FDA approval and with claims research does not support for the conditions advertised. Academic and regulatory sources have separately documented serious adverse events tied to unproven procedures at some clinics, including a peer-reviewed case series published in the New England Journal of Medicine describing patients who suffered severe vision loss after receiving unapproved, unregulated intravitreal "stem cell" injections marketed for macular degeneration — a stark illustration of what can go wrong when a procedure bypasses clinical trial safeguards.

What Actually Varies Between Clinics

• Cell source and processing. Products made in controlled, validated manufacturing facilities under good manufacturing practice differ meaningfully from cells processed same-day in an office setting with inconsistent quality control.
• Regulatory pathway. Whether a treatment went through FDA review, is being tested under an IND with IRB oversight, or is being sold under a claimed (and often disputed) manufacturing exemption changes what evidence exists for it.
• Evidence base. An FDA-approved product has clinical trial data behind it. A clinic's in-house testimonials or small uncontrolled case series are not equivalent evidence, however confidently they are presented.
• Country-to-country regulation. Oversight of cell-based interventions varies significantly by country, and "stem cell tourism" to jurisdictions with looser enforcement is a recognized pattern discussed in the bioethics and regenerative medicine literature.
• Transparency about trial registration. Legitimate trials are typically registered (e.g., on ClinicalTrials.gov) and reviewed by an IRB; direct-to-consumer clinics usually are not conducting registered trials at all, even when they use trial-sounding language.

How to Tell the Difference

Patients evaluating any clinic can reasonably ask: Is this treatment FDA-approved, or part of a registered, IRB-approved clinical trial, or neither? What is the cell source, and how are the cells processed? Can the clinic provide peer-reviewed evidence — not testimonials — for this specific condition? Has the clinic received FDA warning letters or other regulatory action? The International Society for Stem Cell Research (ISSCR) publishes a patient-facing guide specifically designed to help people ask these questions and recognize red flags such as claims that a single treatment works for many unrelated diseases, pressure to pay large sums upfront, or an absence of independent oversight.

Bottom Line

Not all stem cell clinics operate under the same rules, use the same quality controls, or have the same evidence behind their claims. Some offer FDA-approved products or well-designed clinical trials; others sell unapproved procedures with little more than anecdote behind them, and some of those have caused serious, documented harm. The difference is not cosmetic — it is the difference between a treatment vetted through established safety and efficacy review and one that has not been. Asking about regulatory status, cell processing, and the actual evidence base is the most practical way to tell these apart before, not after, a procedure.